[CAS NO. 2349386-89-4] Molnupiravir (EIDD-2801)

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2349386-89-4]

Catelog

SLK-S8969

Brand

Selleck

CAS

2349386-89-4

DESCRIPTION [2349386-89-4]

Overview

MDL	-
Molecular Weight	329.31
Molecular Formula	C13H19N3O7
SMILES	CC(C)C(OC[C@H]1O[C@@H](N(C(N/2)=O)C=CC2=N\O)[C@H](O)[C@@H]1O)=O

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	3.0367 mL	15.1833 mL	30.3665 mL
5 mM	0.6073 mL	3.0367 mL	6.0733 mL
10 mM	0.3037 mL	1.5183 mL	3.0367 mL
50 mM	0.0607 mL	0.3037 mL	0.6073 mL

Description

Molnupiravir (EIDD-2801, MK-4482) is an orally bioavailable prodrug of the ribonucleoside analog β-d-N-hydroxycytidine (NHC; EIDD-1931) with broad-spectrum against , , , and the causative agent of .

Targets

SARS-CoV-2 ^[1]

MERS-CoV ^[1]

SARS-CoV ^[1]

In vitro

EIDD-2801 is an orally bioavailable NHC-prodrug. NHC is potently antiviral against SARS-CoV-2, MERS-CoV and SARS-CoV in primary human epithelial cell cultures without cytotoxicity. NHC is effective against remdesivir (RDV)-resistant vi-rus and multiple distinct zoonotic CoV. NHC antiviral activity is associated with increased viral mutation rates.

References

[1] Sheahan TP, et al. Sci Transl Med. 2020 Apr 29;12(541).
[2] Toots M, et al. Sci Transl Med. 2019 Oct 23;11(515).
[3] Weil T, et al. Antiviral Res. 2022 Jul;203:105343.